Cogent Biosciences, Inc. (COGT) compared with its closest peers (PRLD, RLAY, SION, PGEN, CBIO). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Prelude Therapeutics: names this company as a competitor in its 10-K.
| Company | Market Cap | P/E |
|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $366.30M | — |
| Relay Therapeutics, Inc. (RLAY) | $4.13B | — |
| Sionna Therapeutics, Inc. (SION) | $354.01M | — |
| Precigen, Inc. (PGEN) | $2.45B | — |
| Crescent Biopharma, Inc. (CBIO) | $717.99M | — |
| Zenas BioPharma, Inc. (ZBIO) | $1.97B | — |
| Olema Pharmaceuticals, Inc. (OLMA) | $787.48M | — |
| Bicara Therapeutics Inc. (BCAX) | $1.51B | — |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | $393.66M | — |
| Opus Genetics, Inc. (IRD) | $500.84M | — |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
COGT overview · COGT earnings · COGT financials · COGT KPIs · COGT documents · COGT ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.